Which has higher valuation and earnings, AGMB or SLS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A SELLAS Life Sciences Group N/A N/A -$26.86M -$0.23 N/A

Is AGMB or SLS more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat SELLAS Life Sciences Group's return on equity. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A SELLAS Life Sciences Group N/A -43.49% -39.90%

Does the media refer more to AGMB or SLS?

In the previous week, SELLAS Life Sciences Group had 11 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 13 mentions for SELLAS Life Sciences Group and 2 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.62 beat SELLAS Life Sciences Group's score of 0.51 indicating that AgomAb Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SELLAS Life Sciences Group 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer AGMB or MESO?

AgomAb Therapeutics presently has a consensus target price of $33.00, suggesting a potential upside of 149.62%. Given AgomAb Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe AgomAb Therapeutics is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AgomAb Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Mesoblast 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, AGMB or MESO?

AgomAb Therapeutics has higher earnings, but lower revenue than Mesoblast. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A Mesoblast $65.38M 30.99 -$102.14M -$0.28 N/A

Is AGMB or MESO more profitable?

Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A Mesoblast N/A N/A N/A

Does the media favor AGMB or MESO?

In the previous week, Mesoblast had 1 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 3 mentions for Mesoblast and 2 mentions for AgomAb Therapeutics. Mesoblast's average media sentiment score of 0.86 beat AgomAb Therapeutics' score of 0.62 indicating that Mesoblast is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesoblast 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, AGMB or STOK?

Stoke Therapeutics has higher revenue and earnings than AgomAb Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A Stoke Therapeutics $184.42M 10.94 -$6.89M -$3.34 N/A

Does the media favor AGMB or STOK?

In the previous week, Stoke Therapeutics had 4 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 6 mentions for Stoke Therapeutics and 2 mentions for AgomAb Therapeutics. Stoke Therapeutics' average media sentiment score of 0.78 beat AgomAb Therapeutics' score of 0.62 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, AUPH or AGMB?

Aurinia Pharmaceuticals has higher revenue and earnings than AgomAb Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aurinia Pharmaceuticals $311.51M 6.61 $287.20M $2.29 6.76 AgomAb Therapeutics N/A N/A -$70.77M N/A N/A

Does the media favor AUPH or AGMB?

In the previous week, Aurinia Pharmaceuticals had 4 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 6 mentions for Aurinia Pharmaceuticals and 2 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.62 beat Aurinia Pharmaceuticals' score of 0.48 indicating that AgomAb Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral AgomAb Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, AGMB or ZBIO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A Zenas BioPharma N/A N/A -$377.74M -$8.99 N/A

Is AGMB or ZBIO more profitable?

AgomAb Therapeutics' return on equity of 0.00% beat Zenas BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A Zenas BioPharma N/A -99.99% -58.06%

Does the media refer more to AGMB or ZBIO?

In the previous week, Zenas BioPharma had 8 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 10 mentions for Zenas BioPharma and 2 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.62 beat Zenas BioPharma's score of -0.34 indicating that AgomAb Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

AgomAb Therapeutics (AGMB) Competitors

$13.22 -0.72 (-5.16%)

Closing price 04:00 PM Eastern

Extended Trading

$13.34 +0.13 (+0.95%)

As of 04:10 PM Eastern

Compare

AGMB vs. SLS, MESO, STOK, AUPH, and ZBIO

Should you buy AgomAb Therapeutics stock or one of its competitors? AgomAb Therapeutics's main competitors and comparable companies include SELLAS Life Sciences Group (SLS), Mesoblast (MESO), Stoke Therapeutics (STOK), Aurinia Pharmaceuticals (AUPH), and Zenas BioPharma (ZBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AgomAb Therapeutics compare to SELLAS Life Sciences Group?

AgomAb Therapeutics (NASDAQ:AGMB) and SELLAS Life Sciences Group (NASDAQ:SLS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

In the previous week, SELLAS Life Sciences Group had 11 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 13 mentions for SELLAS Life Sciences Group and 2 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.62 beat SELLAS Life Sciences Group's score of 0.51 indicating that AgomAb Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SELLAS Life Sciences Group	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

AgomAb Therapeutics currently has a consensus target price of $33.00, indicating a potential upside of 149.62%. SELLAS Life Sciences Group has a consensus target price of $10.00, indicating a potential downside of 21.75%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe AgomAb Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

AgomAb Therapeutics' return on equity of 0.00% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
SELLAS Life Sciences Group	N/A	-43.49%	-39.90%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A

Summary

AgomAb Therapeutics beats SELLAS Life Sciences Group on 6 of the 10 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Mesoblast?

AgomAb Therapeutics (NASDAQ:AGMB) and Mesoblast (NASDAQ:MESO) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

1.4% of Mesoblast shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

AgomAb Therapeutics presently has a consensus target price of $33.00, suggesting a potential upside of 149.62%. Given AgomAb Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe AgomAb Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Mesoblast	N/A	N/A	N/A

AgomAb Therapeutics has higher earnings, but lower revenue than Mesoblast.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
Mesoblast	$65.38M	30.99	-$102.14M	-$0.28	N/A

In the previous week, Mesoblast had 1 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 3 mentions for Mesoblast and 2 mentions for AgomAb Therapeutics. Mesoblast's average media sentiment score of 0.86 beat AgomAb Therapeutics' score of 0.62 indicating that Mesoblast is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesoblast	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mesoblast beats AgomAb Therapeutics on 5 of the 9 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Stoke Therapeutics?

AgomAb Therapeutics (NASDAQ:AGMB) and Stoke Therapeutics (NASDAQ:STOK) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

In the previous week, Stoke Therapeutics had 4 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 6 mentions for Stoke Therapeutics and 2 mentions for AgomAb Therapeutics. Stoke Therapeutics' average media sentiment score of 0.78 beat AgomAb Therapeutics' score of 0.62 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stoke Therapeutics has higher revenue and earnings than AgomAb Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
Stoke Therapeutics	$184.42M	10.94	-$6.89M	-$3.34	N/A

AgomAb Therapeutics currently has a consensus target price of $33.00, indicating a potential upside of 149.62%. Stoke Therapeutics has a consensus target price of $43.00, indicating a potential upside of 37.51%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe AgomAb Therapeutics is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

AgomAb Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. AgomAb Therapeutics' return on equity of 0.00% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Stoke Therapeutics	-753.60%	-59.36%	-51.46%

Summary

AgomAb Therapeutics and Stoke Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and AgomAb Therapeutics (NASDAQ:AGMB) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Aurinia Pharmaceuticals has higher revenue and earnings than AgomAb Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$311.51M	6.61	$287.20M	$2.29	6.76
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A

Aurinia Pharmaceuticals currently has a consensus price target of $17.67, suggesting a potential upside of 14.20%. AgomAb Therapeutics has a consensus price target of $33.00, suggesting a potential upside of 149.62%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe AgomAb Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Aurinia Pharmaceuticals has a net margin of 100.84% compared to AgomAb Therapeutics' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat AgomAb Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
AgomAb Therapeutics	N/A	N/A	N/A

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Aurinia Pharmaceuticals had 4 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 6 mentions for Aurinia Pharmaceuticals and 2 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.62 beat Aurinia Pharmaceuticals' score of 0.48 indicating that AgomAb Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aurinia Pharmaceuticals beats AgomAb Therapeutics on 8 of the 12 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Zenas BioPharma?

AgomAb Therapeutics (NASDAQ:AGMB) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

AgomAb Therapeutics' return on equity of 0.00% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Zenas BioPharma	N/A	-99.99%	-58.06%

In the previous week, Zenas BioPharma had 8 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 10 mentions for Zenas BioPharma and 2 mentions for AgomAb Therapeutics. AgomAb Therapeutics' average media sentiment score of 0.62 beat Zenas BioPharma's score of -0.34 indicating that AgomAb Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

AgomAb Therapeutics currently has a consensus target price of $33.00, suggesting a potential upside of 149.62%. Zenas BioPharma has a consensus target price of $45.71, suggesting a potential upside of 54.91%. Given AgomAb Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe AgomAb Therapeutics is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
Zenas BioPharma	N/A	N/A	-$377.74M	-$8.99	N/A

Summary

AgomAb Therapeutics beats Zenas BioPharma on 6 of the 8 factors compared between the two stocks.

Get AgomAb Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGMB vs. The Competition

Export

Metric	AgomAb Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$479.09M	$3.71B	$6.97B	$13.04B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	N/A	10.68	269.86	25.30
Price / Sales	N/A	1,305.14	601.47	101.06
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	1.55	17.49	13.08	6.33
Net Income	-$70.77M	-$13.32M	$3.45B	$347.70M
7 Day Performance	-8.83%	1.74%	1.12%	1.07%
1 Month Performance	9.80%	1.60%	1.79%	1.03%
1 Year Performance	N/A	56.43%	67.69%	20.77%

AgomAb Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGMB AgomAb Therapeutics	2.393 of 5 stars	$13.22 -5.2%	$33.00 +149.6%	N/A	$479.09M	N/A	N/A	62
SLS SELLAS Life Sciences Group	0.6543 of 5 stars	$11.05 +0.1%	$10.00 -9.5%	+700.0%	$2.17B	N/A	N/A	10	Earnings Report Analyst Forecast Options Volume
MESO Mesoblast	0.2664 of 5 stars	$16.92 +1.4%	N/A	+8.6%	$2.17B	$17.20M	N/A	80	Positive News Gap Up
STOK Stoke Therapeutics	2.8904 of 5 stars	$32.96 +2.3%	$43.00 +30.5%	+85.2%	$2.08B	$27.59M	N/A	100
AUPH Aurinia Pharmaceuticals	3.5811 of 5 stars	$15.37 -0.5%	$17.67 +14.9%	+26.4%	$2.06B	$283.05M	6.71	300	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGMB) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AgomAb Therapeutics (AGMB) Competitors

AGMB vs. SLS, MESO, STOK, AUPH, and ZBIO

How does AgomAb Therapeutics compare to SELLAS Life Sciences Group?

Summary

How does AgomAb Therapeutics compare to Mesoblast?

Summary

How does AgomAb Therapeutics compare to Stoke Therapeutics?

Summary

How does AgomAb Therapeutics compare to Aurinia Pharmaceuticals?

Summary

How does AgomAb Therapeutics compare to Zenas BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGMB vs. The Competition

AgomAb Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AgomAb Therapeutics (AGMB) Competitors

AGMB vs. SLS, MESO, STOK, AUPH, and ZBIO

How does AgomAb Therapeutics compare to SELLAS Life Sciences Group?

Does the media refer more to AGMB or SLS?

Do insiders and institutionals hold more shares of AGMB or SLS?

Do analysts recommend AGMB or SLS?

Is AGMB or SLS more profitable?

Which has higher valuation and earnings, AGMB or SLS?

Summary

How does AgomAb Therapeutics compare to Mesoblast?

Do insiders & institutionals hold more shares of AGMB or MESO?

Do analysts prefer AGMB or MESO?

Is AGMB or MESO more profitable?

Which has higher earnings and valuation, AGMB or MESO?

Does the media favor AGMB or MESO?

Summary

How does AgomAb Therapeutics compare to Stoke Therapeutics?

Does the media favor AGMB or STOK?

Which has higher earnings and valuation, AGMB or STOK?

Do analysts recommend AGMB or STOK?

Is AGMB or STOK more profitable?

Summary

How does AgomAb Therapeutics compare to Aurinia Pharmaceuticals?

Which has preferable earnings and valuation, AUPH or AGMB?

Do analysts recommend AUPH or AGMB?

Is AUPH or AGMB more profitable?

Do institutionals and insiders have more ownership in AUPH or AGMB?

Does the media favor AUPH or AGMB?

Summary

How does AgomAb Therapeutics compare to Zenas BioPharma?

Is AGMB or ZBIO more profitable?

Does the media refer more to AGMB or ZBIO?

Do analysts rate AGMB or ZBIO?

Which has better valuation & earnings, AGMB or ZBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGMB vs. The Competition

AgomAb Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools